UCB’s efforts to build a franchise of therapies for muscle-wasting disease generalised myasthenia gravis have taken another step forwards after the CHMP recommended approv
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hope
The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be u
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh